Finance
EU Approves Higher Dose of Novo Nordisk's Wegovy
Published by Global Banking & Finance Review®
Posted on February 17, 2026
1 min readLast updated: February 17, 2026
Add as preferred source on GoogleGlobal Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on February 17, 2026
1 min readLast updated: February 17, 2026
Add as preferred source on GoogleThe European Commission approved a higher dose of Novo Nordisk's weight-loss drug Wegovy, potentially enhancing its effectiveness.
Feb 17 (Reuters) - Novo Nordisk said on Tuesday the European Commission has approved a higher dose of its popular obesity drug Wegovy, providing patients and doctors with an option that may support greater weight loss.
The decision follows a positive recommendation from the European Union's drug regulator in December for the drug's 7.2 milligram dose.
With the approval, doctors in the EU may now prescribe the 7.2 mg dosage as three 2.4 mg injections, to be taken in one sitting, once a week, the Danish drugmaker said.
In a 72-week late-stage trial involving 1,407 adults without diabetes, participants on the 7.2 mg dose lost an average of 20.7% of body weight, compared with 17.5% for the 2.4 mg dose.
Novo has also applied for an EU approval of a 7.2 mg single-dose pen. If approved, this could be available this year, the company said.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Wegovy is a prescription medication developed by Novo Nordisk for weight management. It is used alongside a reduced-calorie diet and increased physical activity to help individuals lose weight and maintain weight loss.
The European Commission is the executive branch of the European Union responsible for proposing legislation, implementing decisions, and managing the day-to-day operations of the EU.
Weight loss medication is a type of pharmaceutical drug designed to help individuals lose weight by suppressing appetite, increasing feelings of fullness, or reducing the absorption of fat.
Explore more articles in the Finance category
